Lyos

TEAM II - Bone, Cancers and Metastases

INSERM UMR 1033 - TEAM II

UFR de Médecine Lyon-Est - 2ème étage rue Guillaume Paradin, 69372 Lyon cedex08 – France | Phone : +33(0)4 78 77 10 77

LYOS – INSERM U1033,
Team «Bone, Cancers and Metastases»,

Université de Lyon, France.

Top 10 publications over the past 5 years

 

  1. CROSET M, PANTANO F, KAN CWS, BONNELYE E, DESCOTES F, ALIX-PANABIÈRES C, LECELLIER CH, BACHELIER R, ALLIOLI N, HONG SS, BARTKOWIAK K, PANTEL K, CLÉZARDIN P. MicroRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes.Cancer Res. 2018Jul 24. pii: canres.3058.2017. doi: 10.1158/0008-5472.CAN-17-3058. 8(34):56460-72.
  2. SOUSA S, CLÉZARDIN P. Bone-Targeted Therapies in Cancer-Induced Bone Disease.Calcif Tissue Int. 2018; 102(2):227-250.
  3. BOUDOT C, HÉNAUT L, THIEM U, GERACI S, GALANTE M, SALDANHA P, SAIDAK Z, SIX I, CLÉZARDIN P, KAMEL S, MENTAVERRI R. Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation. Oncotarget. 2017; 8(34):56460-72.
  4. REYNAUD C, FERRERAS L, DI MAURO P, KAN C, CROSET M, BONNELYE E, PEZ F, THOMAS C, AIMONT G, KARNOUB AE, BREVET M, CLEZARDIN P. Lysyl oxidase is a strong determinant of tumor cell colonization in bone. Cancer Res. 2017; 77(2):268-278.
  5. FRADET A, BOUCHET M, DELLIAUX C, GERVAIS M, KAN C, BENETOLLO C, PANTANO F, VARGAS G, BOUAZZA L, CROSET M, BALA Y, LEROY X, ROSOL TJ, RIEUSSET J, BELLAHCÈNE A, CASTRONOVO V, AUBIN JE, CLÉZARDIN P, DUTERQUE-COQUILLAUD M, BONNELYE E. Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone. Oncotarget 2016, 7(47):77071-86.
  6. HADJI P, COLEMAN RE, WILSON C, POWLES TJ, CLÉZARDIN P, AAPRO M, COSTA L, BODY JJ, MARKOPOULOS C, SANTINI D, DIEL I, DI LEO A, CAMERON D, DODWELL D, SMITH I, GNANT M, GRAY R, HARBECK N, THURLIMANN B, UNTCH M, CORTES J, MARTIN M, ALBERT US, CONTE PF, EJLERTSEN B, BERGH J, KAUFMANN M, HOLEN I. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol. 2016; 27(3):379-90.
  7. TARDOSKI S, NGO J, GINEYTS E, ROUX JP, CLÉZARDIN P*, MELODELIMA D*. (*: equal contributors) Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer. Sci Rep. 2015; 5:16354.
  8. SAHAY D, LEBLANC R, GRUNEWALD TG, AMBATIPUDI S, RIBEIRO J, CLEZARDIN P, PEYRUCHAUD O. The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. Oncotarget. 2015; 6(24):20604-20.
  9. CROSET M, GOEHRIG D, FRACKOWIAK A, BONNELYE E, ANSIEAU S, PUISIEUX A, CLEZARDIN P. TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J Bone Miner Res. 2014; 29:1886-99.
  10. BACHELIER R, CONFAVREUX CB, PEYRUCHAUD O, CROSET M, GOEHRIG D, van der PLUIJM G, CLÉZARDIN P. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis. Int J Cancer. 2014 Sep 15; 135(6):1319-29.